British drugmaker GSK said today that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of tumour.



tag:reuters.com,2022:binary_RC2OTV97GEV9-BASEIMAGE

RTÉ

Ireland

GSK to buy US biotech firm IDRx for up to $1.15 billion

The acquisition of IDRx will help GSK target a ‘major gap in the current standard of care’ related to gastrointestinal cancers.

Ad Fontes Media

All Sides

Media Bias/Fact Check

The Independent

Evgeny Lebedev

London

Greater London

England

United Kingdom

GSK buys US-based rare cancer treatment developer for up to £1bn

British drugmaker GSK said today that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of tumour.

Government of Ireland

The British pharma giant plans to shell out $1 billion upfront to buy the drug developer working on a lead treatment for gastrointestinal stromal tumors.

The Business Journals

Advance Publications

United States

GSK shells out $1B upfront for Plymouth cancer biotech

Business Analysis
The year 2025 may turn out to be a good one for mergers and acquisitions (M&A). Two weeks into the new year, merger activity is picking up steam. After the surprise announcement of the mergers between JCPenney and Sparc Group, and between Constellation and Calpine last week, GSK and IDRx followed suit on Jan. 13, adding cheer to otherwise gloomy financial markets.
The British drugmaker will pay $1.15 billion for privately held …

The Epoch Times

Epoch Media Group

New York

GSK to Buy IDRx for $1.15 Billion as Mergers and Acquisitions Pick up Steam in 2025

Boston-based biotechnology firm developing therapy for treatment of gastrointestinal stromal tumors - Anadolu Ajansı

Anadolu Ajansı

Government of Turkey

Ankara

Turkey

GSK to buy US biopharmaceutical company IDRx for $1.15B

British pharmaceutical company GSK on Monday said it had agreed to buy a US company that specializes in the treatment of rare gastrointestinal cancer GIST.

Medical Xpress

Drugmaker GSK buys US firm focused on gastro cancer

British drugmaker GSK agrees to acquire Boston-based biopharmaceutical firm IDRx for up to $1.15 billion, with an initial $1 billion payment. IDRx develops a treatment for gastrointestinal stromal tumours, contributing to GSK's expanding portfolio in gastrointestinal cancers amid its vaccine business challenges.

The Economic Times

Sahu Jain family

GSK (GSK) finalized the deal to acquire Boston-based, clinical-stage biopharmaceutical company—IDRx for a total of up to $1.15 billion cash consideration.

Seeking Alpha

GSK to buy Boston-based IDRx for $1.15 billion (NYSE:GSK)

The British pharmaceutical company GlaxoSmithKline (GSK) announced on Monday that it reached an agreement to acquire IDRx, an American laboratory specializing in oncological treatments, for up to $1.1 billion. According to the press release, GSK will make an advance payment of $1 billion and an additional $150 million, which is conditional on milestones. The transaction includes the compound IDRX-42, a tyrosine kinase inhibitor, designed to figh…

La farmacéutica británica GlaxoSmithKline (GSK) anunció el lunes que llegó a un acuerdo para adquirir IDRx, un laboratorio estadounidense especializado en tratamientos oncológicos, por hasta $1.150 millones.Según la nota de prensa, GSK realizará un pago por adelantado de $1.000 millones y otro adicional de $150 millones, que está condicionado a cumplir hitos. La transacción incluye el compuesto IDRX-42, un inhibidor de la tirosina quinasa, diseñ…

Laboratorio británico GSK comprará biotecnológica estadounidense IDRx por hasta $1.150 millones

La Nación, Grupo Nación

British laboratory GSK will buy U.S. biotechnology IDRx for up to $1.150 million

IDRx, a privately held biotechnology firm, is developing a therapy for the treatment of gastrointestinal stromal tumours

Zawya

GSK to buy US biotech firm IDRx for up to $1.15bln

Cancer

Europe

Business

European Economy

Health

UK Economy

Medical

Business Times

STAT

Nairametrics

pipelinereview

stocktitan.net

perspectivemedia.com

humenglish.com

diarioestrategia.cl

Endpoints News

ramaonhealthcare.com

abbonews.com

Pharmaphorum

DirectorsTalk Interviews

OODA Loop

pharmaceutical-technology.com

InsideBusiness - Business News in Nigeria

GeneOnline News

GSK shells out $1B upfront for Plymouth cancer biotech

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics